TIDMPXS
RNS Number : 8121D
Provexis PLC
30 October 2020
30 October 2020
Provexis plc
("Provexis" or the "Company")
Result of AGM
Provexis, the business that develops, licenses and sells the
proprietary, scientifically-proven Fruitflow(R) heart-health
functional food ingredient, announces that at the Company's Annual
General Meeting, held earlier today, all resolutions were duly
passed. The proxy votes received from shareholders on each
resolution are set out below.
Resolutions Votes for % Votes against % Votes total Votes withheld
* ** ***
Resolution
1 490,158,473 99.86 710,000 0.14 490,868,473 257,475
Resolution
2 487,328,865 99.80 960,000 0.20 488,288,865 2,837,083
Resolution
3 486,429,442 99.80 960,000 0.20 487,389,442 3,736,506
Resolution
4 481,796,829 99.50 2,423,324 0.50 484,220,153 6,905,795
Resolution
5 479,104,122 98.48 7,384,133 1.52 486,488,255 4,637,693
Resolution
6 477,943,511 98.22 8,674,744 1.78 486,618,255 4,507,693
Resolution
7 488,348,335 99.61 1,903,901 0.39 490,252,236 873,712
* Includes discretionary votes
** Total votes cast do not include withheld votes
*** A vote withheld is not a vote in law and is not counted
in the calculation of the proportion of votes 'For' or
'Against' any of the resolutions
For further information please contact:
Provexis plc Tel: 07490 391888
Dawson Buck, Chairman enquiries@provexis.com
Ian Ford, CEO
Allenby Capital Limited Tel: 020 3328 5656
Nick Naylor / Liz Kirchner
Notes for editors
About Provexis plc
AIM-listed Provexis is focused on the development, licensing and
sales of its proprietary, scientifically-proven Fruitflow(R)
heart-health functional food ingredient.
Fruitflow is a natural, breakthrough ingredient that helps with
platelet aggregation. This helps promote normal blood flow and
circulation, which in turn benefits cardiovascular health.
Fruitflow helps the platelets to circulate freely and smoothly
throughout your blood, without sticking to one another or to the
blood vessels themselves. Freely flowing blood helps reduce stress
on your cardiovascular system.
Fruitflow is a highly concentrated form of bioactives which is
lycopene-free and contains over 30 known anti-platelet compounds.
Published clinical studies have shown that Fruitflow works to
maintain healthy blood flow in a similar way to 75mg aspirin but
with a milder and reversible action; Fruitflow has a similar
antiplatelet effect to a single dose of aspirin - but when taken
daily, it has none of aspirin's side effects.
The science behind Fruitflow has been validated by leading peer
review publications and regulatory authorities. Fruitflow is the
only natural antiplatelet to have a health claim approved by the
European Food Safety Authority, stating that 150mg of Fruitflow
'helps maintain normal platelet aggregation, which contributes to
healthy blood flow'.
Provexis plc entered into a long-term Alliance Agreement with
DSM Nutritional Products in 2010 to commercialise Fruitflow through
sales as an ingredient to brand owners in the food, beverage and
dietary supplement categories. More than 90 regional consumer
healthcare brands have now been launched by direct customers of
DSM, and a number of further regional brands have been launched
through DSM's distributor channels.
Fruitflow has a number of specific health benefits which have
been reflected in separate patent filings for the use of Fruitflow
in:
-- mitigating exercise-induced inflammation;
-- managing blood pressure; and
-- Protecting against the adverse effects of air pollution on
the body's cardiovascular system. Laboratory work has shown that
Fruitflow can reduce the platelet activation caused by airborne
particulate matter, such as that from diesel emissions, by
approximately one third.
Provexis sells a high quality dietary supplement product
containing Fruitflow and Omega-3 from its separate website
www.fruitflowplus.com on a mail order basis. The product is also
available to purchase from Amazon.co.uk and from Holland &
Barrett.
The Company is working closely with By-health Co., Ltd, a
GBP4.5bn listed Chinese dietary supplement business, to support the
planned launch of some Fruitflow based products in the Chinese
market. The planned launch is progressing well with potential sales
volumes remaining at a significant multiple of existing Fruitflow
sales.
By-Health has made a significant investment in nine separate
clinical studies in China, at its sole expense, in support of the
Fruitflow based products which it plans to launch in China. The
five studies which have been completed by By-Health showed
excellent results in use for Fruitflow, and provide strong evidence
for By-Health in its regulatory submissions for Fruitflow.
If a successful blue cap health claim is achieved for Fruitflow
in China it would currently be expected to result in some
significant recurring orders for Fruitflow, at a multiple of
current total sales values.
COVID-19
The Company and DSM have experienced increased consumer interest
for Fruitflow in recent months, in light of the COVID-19 pandemic,
as consumers look to nutritional interventions to help them fortify
the circulatory system against the effects of COVID-19. The Company
and DSM will look to maximise the commercial opportunities arising
from this increased consumer interest in Fruitflow, and will
further promote the core blood circulatory and anti-inflammatory
benefits of the product.
In September 2020 Fruitflow was recognised in a review article
by the Frontiers in Nutrition journal
www.frontiersin.org/articles/10.3389/fnut.2020.583080/full which
stated that nutraceuticals such as Fruitflow may serve as:
'A safe antiplatelet prophylactic treatment for those at high
risk of COVID-19 who may also be at increased risk of thrombotic
complications and an alternative to pharmacological compounds that
may cause greater risk of bleeding.'
Provexis was founded in 1999 and is headquartered in Reading,
Berkshire.
Provexis shares are traded on the AIM market of the London Stock
Exchange under the ticker symbol PXS.
For further information, please visit www.provexis.com and
www.fruitflowplus.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGZBLFXBBLBFBV
(END) Dow Jones Newswires
October 30, 2020 10:09 ET (14:09 GMT)
Provexis (AQSE:PXS.GB)
Historical Stock Chart
From Mar 2025 to Apr 2025
Provexis (AQSE:PXS.GB)
Historical Stock Chart
From Apr 2024 to Apr 2025
